➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
AstraZeneca
McKesson
Baxter
Merck

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

Liebel-flarsheim Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for LIEBEL-FLARSHEIM, and what generic and branded alternatives to LIEBEL-FLARSHEIM drugs are available?

LIEBEL-FLARSHEIM has eleven approved drugs.



Summary for Liebel-flarsheim
US Patents:0
Tradenames:14
Ingredients:5
NDAs:11

Drugs and US Patents for Liebel-flarsheim

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Liebel-flarsheim OPTIRAY 350 ioversol INJECTABLE;INJECTION 020923-003 May 28, 1998 RX Yes Yes   Start Trial   Start Trial
Liebel-flarsheim OPTIRAY 300 ioversol INJECTABLE;INJECTION 019710-004 Jan 22, 1992 RX Yes Yes   Start Trial   Start Trial
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-001 Dec 8, 1999 DISCN Yes No   Start Trial   Start Trial
Liebel-flarsheim CONRAY iothalamate meglumine INJECTABLE;INJECTION 013295-001 Approved Prior to Jan 1, 1982 RX Yes Yes   Start Trial   Start Trial
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-004 Dec 8, 1999 DISCN Yes No   Start Trial   Start Trial
Liebel-flarsheim OPTIMARK IN PLASTIC CONTAINER gadoversetamide INJECTABLE;INJECTION 020976-002 Dec 8, 1999 DISCN Yes No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Liebel-flarsheim

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-002 Dec 8, 1999 5,137,711   Start Trial
Liebel-flarsheim OPTIRAY 350 ioversol INJECTABLE;INJECTION 019710-005 Jan 22, 1992 4,396,598   Start Trial
Liebel-flarsheim OPTIRAY 240 ioversol INJECTABLE;INJECTION 020923-001 May 28, 1998 4,396,598   Start Trial
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020975-001 Dec 8, 1999 5,130,120   Start Trial
Liebel-flarsheim OPTIRAY 240 ioversol INJECTABLE;INJECTION 019710-002 Dec 30, 1988 4,396,598   Start Trial
Liebel-flarsheim OPTIMARK gadoversetamide INJECTABLE;INJECTION 020937-003 Dec 8, 1999 5,130,120   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Merck
Johnson and Johnson
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.